Aktuellt
SENASTE
Redeye provides an update in relation to Optomed’s Q1 2023 report. The sales amounted to EUR3.5m (EUR3.2m), and EBIT came in at EUR-1,0m (EUR-1.5), which was fairly in line with our expectations and estimates. We have chosen to only make some minor changes in our 2023e sales estimate due to the slight delay in the FDA process. Moreover, we believe there are exciting times ahead of us and reiterate our base case of EUR8.
LÄS MER
